MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM (Dextromethorphan Hydrobromide; Guaifenesin; Naproxen Sodium) Patent Expiration, LOE Window & CMS Spending

MUCINEX 12HR COLD & FEVER MULTI-SYMPTOM (Dextromethorphan Hydrobromide; Guaifenesin; Naproxen Sodium) by Reckitt Benckiser: FDA Orange Book core substance LOE 2036-10-11, 0 AB generics, $0 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorReckitt Benckiser
FDA Application & PathwayN217338 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2036-10-11
Last Listed Patent or Exclusivity Date2036-10-11
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel